(Q36470451)

14 August 2017

1 reference

title

Considerations in the long-term management of asthma in ambulatory patients (English)

1 reference

14 August 2017

0 references

Dennis M Williams

1

1 reference

14 August 2017

publication date

1 May 2006

1 reference

American Journal of Health-System Pharmacy

14 August 2017

published in

1 reference

14 August 2017

volume

63

1 reference

14 August 2017

issue

10 Suppl 3

1 reference

14 August 2017

page(s)

S14-21

1 reference

Assessment of asthma control and severity.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Long-term effects of budesonide or nedocromil in children with asthma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Low-dose inhaled corticosteroids and the prevention of death from asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Growth and bone density in children with mild-moderate asthma: a cross-sectional study in children entering the Childhood Asthma Management Program (CAMP)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Daily versus as-needed corticosteroids for mild persistent asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Serious asthma exacerbations in asthmatics treated with high-dose formoterol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060128

31 March 2020

Identifiers

DOI

10.2146/AJHP060128

1 reference

14 August 2017

1 reference